Trial reportNeuro-oncology2023
Association of circulating markers with cognitive decline after radiation therapy for brain metastasis.
Trial report in Neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT01372774 (A Phase III Trial of Post-Surgical Stereotactic Radiosurgery), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared With Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Predicting late radiation-associated neurocognitive and endocrine toxicity in patients with brain tumors.Journal of neuro-oncology · 2026Article
- Radiation-Induced Neurodegeneration.Biomedicines · 2026Review
- Radiotherapy-induced neurocognitive decline among adult intracranial tumor patients: A voxel-based approach.Neuro-oncology · 2025Article
- The impact of citicoline on brain mitochondrial dysfunction induced in rats after head irradiation.Scientific reports · 2025Article
- Focusing attention on brain metastasis: Hot issues.Neuro-oncology practice · 2025Article
- Amyloid-beta metabolism in age-related neurocardiovascular diseases.European heart journal · 2025Review
- Radiation-Induced Brain Injury: Mechanistic Insights and the Promise of Gut-Brain Axis Therapies.Brain sciences · 2024Review
- Multi-stage mechanisms of tumor metastasis and therapeutic strategies.Signal transduction and targeted therapy · 2024Review
- Impact of Apolipoprotein E Genotype on Neurocognitive Function in Patients With Brain Metastases: An Analysis of NRG Oncology's RTOG 0614.International journal of radiation oncology, biology, physics · 2024Article
- Neurotoxicity from Old and New Radiation Treatments for Brain Tumors.International journal of molecular sciences · 2023Review
- A brain metastasis liquid biopsy: Where are we now?Neuro-oncology advancesReview
Corrections and comments
- Erratum issued
Authors and funding
25 authors at 13 institutions in 2 countries.
Funding
Abstract
backgroundA recent phase III trial (NCT01372774) comparing use of stereotactic radiosurgery [SRS] versus whole-brain radiation therapy [WBRT] after surgical resection of a single brain metastasis revealed that declines in cognitive function were more common with WBRT than with SRS. A secondary endpoint in that trial, and the primary objective in this secondary analysis, was to identify baseline biomarkers associated with cognitive impairment after either form of radiotherapy for brain metastasis. Here we report our findings on APOE genotype and serum levels of associated proteins and their association with radiation-induced neurocognitive decline.
methodsIn this retrospective analysis of prospectively collected samples from a completed randomized clinical trial, patients provided blood samples every 3 months that were tested by genotyping and enzyme-linked immunosorbent assay, and results were analyzed in association with cognitive impairment.
resultsThe APOE genotype was not associated with neurocognitive impairment at 3 months. However, low serum levels of ApoJ, ApoE, or ApoA protein (all P < .01) and higher amyloid beta (Aβ 1-42) levels (P = .048) at baseline indicated a greater likelihood of neurocognitive decline at 3 months after SRS, whereas lower ApoJ levels were associated with decline after WBRT (P = .014).
conclusionsPatients with these pretreatment serum markers should be counseled about radiation-related neurocognitive decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.